GLP-1 tapering: what employers need to know

The standard assumption in GLP-1 coverage is that once an employee starts, they stay on medication indefinitely. It’s treated like a chronic therapy — similar to a statin — where discontinuation means relapse. That assumption is costing employers millions of dollars they don’t need to spend.

Why tapering matters: the weight regain problem

When patients stop GLP-1 medications abruptly, the results are well-documented. A 2025 meta-analysis published in eClinicalMedicine analyzed 18 randomized controlled trials and found that discontinuing GLP-1 therapy leads to significant metabolic rebound: an average body weight gain of 5.63 kg, along with deterioration in blood sugar, waist circumference, and blood pressure. In the STEP-10 trial, over 40% of lost weight was regained within 28 weeks of stopping semaglutide.

For employers, this creates a specific financial problem. An employee who achieves 15% weight loss, stops medication, regains the weight, and eventually restarts is driving costs in two directions simultaneously — pharmacy spend during active treatment, and rising cardiometabolic claims during the regain period.

What the research shows about tapering

Embla’s TRIM study across 2,694 real-world participants over 64 weeks, published in Diabetes, Obesity and Metabolism, achieved 16.7% average weight loss, with 78.5% of participants successfully tapering or ceasing GLP-1 medication by the end of the program. The average semaglutide dose was just 1.08 mg/week — approximately one-third of the standard maximum. The protocol begins tapering at month 16 over a 12-week period, timed to coincide with behavioral habit consolidation.

Why most GLP-1 programs don’t include tapering

The market is dominated by two types of GLP-1 coverage models: PBM-managed pharmacy benefits and medication-focused telehealth platforms. In both models, the financial incentive runs against tapering. PBMs earn based on drug volume. Telehealth platforms earn based on active subscribers. A program designed to reduce medication use is structurally misaligned with how most GLP-1 vendors make money.

What a real tapering protocol looks like

A well-designed tapering protocol has four components: treat-to-target dosing from the start; a behavioral foundation built before tapering begins; gradual dose reduction over 10–16 weeks; and maintenance support post-cessation. Embla’s protocol starts tapering at month 16, over 12 weeks. The published taper success rate is 78.5%.

What this means for your benefits budget

Under a standard model, an employee enrolled in GLP-1 coverage at 2.4 mg/week generates roughly $900/month in pharmacy costs indefinitely. Over three years, that’s approximately $32,400 in drug spend. Under a treat-to-target, tapering model, average dose is 1.08 mg/week — reducing monthly drug cost by approximately two-thirds — and 78.5% taper off medication entirely, reducing ongoing cost to the program fee only.

The question to ask every GLP-1 vendor

When evaluating any GLP-1 benefit vendor, ask directly: does your program include a published, outcomes-backed tapering protocol? If the answer is no, that’s a signal. The TRIM study demonstrated 78.5% taper success at scale in a real-world population. A benefit that cannot demonstrate tapering outcomes is, by design, a benefit that assumes indefinite medication use.

Embla’s protocol achieves 78.5% taper success. Fully managed. No plan integration. See the clinical evidence →